A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2017
At a glance
- Drugs ARX 788 (Primary)
- Indications Breast cancer; Gastric cancer
- Focus Adverse reactions; First in man
- Sponsors Zhejiang Medicine
- 26 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
- 26 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2018.
- 17 Aug 2016 According to Ambrx media release, the US IND is active and will open US sites for this trial.